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1. General introduction6 
 
1.1. Use of GMO in food production 
 
Imported GMOs are generally used to make compound feed stuffs that are fed to livestock. About 
80% of compound feed stuffs contain GMOs7. There is currently no cultivation of GMOs in Belgium, 
mainly because there are no GM crops approved for cultivation that are relevant for Belgian 
agriculture. The different regions in Belgium have a different approach to the use of GMOs in 
agriculture. The Walloon and Brussels-Capital Region have implemented co-existence regulations 
that are meant to discourage the cultivation of GM crops89. In their vision, the use of GM crops is not 
compatible with the agriculture that they wish to promote10. In the Flemish region a different 
approach is taken. The Flemish government does not stimulate the use of GM crops, but is of the 
opinion that GM crops that are proven to be safe and have a market authorization should be 
available for farmers to allow a free choice. The co-existence legislation in Flanders neither 
encourages nor discourages the use of GM crops, but is built to enable that freedom of choice. 
 
Overall, the public opinion in Belgium about the use of GMOs in food production is not negative, be it 
that in the Walloon Region it may be less positive than in the Flemish Region. A survey held by EOS 
magazine and a recent survey among students of Ghent University showed a rather positive attitude 
towards the use of certain GMOs in food production. There is however also a strong minority opinion 
against GMOs that attracts quite some attention. 
 
 
1.2. Food security 
 
There is no legal definition of food/feed security in Belgium, but in a White Book about Agriculture of 
Flanders, the crisis in food security is mentioned as one of the important external developments that 
need to shape agricultural research11.  
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Environmental policy in Belgium falls largely within the remit of the three autonomous regions: the 
Flemish Region, the Walloon Region and the Brussels-Capital Region. This is particularly the case for 
environmental protection and nature conservation (Art. 6(1), III, of the Special Act of 8 August 1980 
on institutional reform (further: SAIR))12 and, to a large extent, for agricultural policy. However, in 
some areas relevant to the subject matter dealt with, the federal authority is competent. Pursuant to 
the first point of the second paragraph of Article 6(1) SAIR, the federal Government is responsible for 
drawing up product standards. Product standards are defined as “standards that establish the degree 
of pollution or nuisance which may not be exceeded in the composition or during the emission of a 
product, or which include specifications concerning product characteristics, methods of use, sampling 
standards, packaging, marking and labelling”. A product standard is applicable when the product is 
placed on the market, inter alia, at the time of its introduction, importation or possession, for the 
purpose of sale or making available to a third party, offer for sale, offer for rent, rent etc.13 
Requirements relating to environmental protection that apply after the product has been placed on 
the market, such as those concerning the use or release of products, come under the power of the 
Regions and not of the federal authorities14. In the same sense the federal authority is competent to 
set standards (and control them) concerning the quality of primary materials used in agriculture and 
products derived from plants with a view to ensure food safety during the complete production chain 




As with all EU countries, the regulations for GMOs are to a large extent dictated by the EU regulatory 
framework for GMOs.  
   
The implementation of the relevant European Directives concerning GMOs and the application of the 
related Regulations in Belgium is a mixed competence between the regions and the Federal 
Government.  
 
The implementation of Directive 2001/18/EC of the European Parliament and of the Council of 12 
March 2001 on the deliberate release into the environment of genetically modified organisms, and 
repealing Council Directive 90/220/EEC15, is a task for the federal authorities in as far as it deals with 
the “placing on the market of genetically modified organisms as or in products within the 
Community” (Art. 1, second indent). The regional authorities are involved as far as it deals also with 
“carrying out the deliberate release into the environment of genetically modified organisms for any 
other purposes than placing on the market” (Art. 5-11).  Regional competencies are e.g. involved in 
the authorisation of field experiments, because there may be risks to their environment and 
biodiversity. 
 
The implementation of Directive 2009/41/EC of the European Parliament and of the Council of 6 May 
2009 on the contained use of genetically modified micro-organisms is mainly a competence of the 
regions, because the laboratories in which these activities take place are seen as so-called “classified 
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installations” that require a regional environmental permit. Indeed, the Regions are competent with 
regard to what is described in the SAIR as: "the policing of dangerous, unhealthy and noxious 
establishments, subject to measures of internal policy concerning worker protection." This means that 
the Regions are competent for the environmental supervision of potentially noxious installations, for 
example, by a system of notifications and licence requirements, and in some cases more modern 
instruments, such as environmental impact assessment and safety reports. This competence 
comprises both preventive supervision (licences, standards) and curative supervision (e.g., safety 
measures).  
 
The decisions made by different administrative bodies are based on a common scientific evaluation 
system comprising the Biosafety Advisory Council (BAC) and the Biosafety and Biotechnology Unit 
(SBB). The BAC must be consulted for the deliberate release of GMOs in the environment and the 
placing on the market of all GMOs and GMOs-based products; the SBB on contained use activities 
with GMOs and pathogens. The Council can be consulted by the Regions or the SBB for contained use 
activities. More information is available on the website of the Biosafety Advisory Council16. 
 
Federal competencies are involved as well, however, as Article 13 deals with emergency plans for 
such premises. The federal government is competent with regard to civil protection and this 
comprises, inter alia, plans for dealing with disasters, and a coordinated action of the emergency 
services in the event of environmental disasters. 
 
The application of Regulation (EC) N° 1829/2003 of the European Parliament and of the Council of 22 
September 2003 on genetically modified foods and feeds17 is a federal competence. The same is true 
for Regulation (EC) N° 1830/2003 of the European Parliament and of the Council of 22 September 
2003 concerning the traceability and labelling of genetically modified organisms and the traceability 
of food and feed products produced from genetically modified organisms and amending Directive 
2001/18/EC, and Regulation (EC) No 1946/2003 of the European Parliament and of the Council of 15 
July 2003 on transboundary movements of genetically modified organisms. 
 
Given this historically grown division of competencies it is obvious that it was impossible  in Belgium 
to regulate the whole issue in one piece of legislation applicable for the whole country. The solution 
that was chosen is a combination of a cooperation agreement between federal and regional 
authorities, on the one hand, and federal and regional acts and regulations on the other. 
 
The relevant legal framework in Belgium is essentially constituted by18: 
 
a) The Cooperation Agreement of 25 April 1997 between the Federal State and the Regions on 
the administrative and scientific coordination concerning biosafety. This cooperation agreement 
concerns not only GMOs and GMMs, but also organisms that are human pathogens. The Cooperation 
Agreement establishes a common scientific evaluation system for all biosafety-related matters. It is 
composed of the Biosafety Advisory Council19, which is charged with the task of evaluating the 
biosafety of activities or products for which GMMs, GMOs or parts thereof are used and of the 
contained use of human pathogenic micro-organisms, and with offering advice in the context of the 
Cooperation Agreement. The secretariat of the Council is assumed by the Biosafety and 
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Biotechnology Unit SBB) of the Scientific Institute of Public Health (WIV-ISP). The SBB is composed of 
an administrative secretariat, and a multidisciplinary group of scientists. 
 
b) The Royal Decree of 21 February 2005 regulating the deliberate release into the environment 
and placing on the market of genetically modified organisms as or in products20. This Royal Decree 
transposes Directive 2001/18/EC (territory covered: the whole of Belgium).  This Royal Decree was 
adopted with some delay21. This delay was mainly due to disagreement on the way in which the 
Directive was to be transposed into Belgian law. The Minister of Consumer Affairs, Public Health and 
the Environment of the Green Party, had framed a preliminary draft which in some respects went 
further than what was prescribed by the Directive. One of the controversial points was that for each 
individual application to authorize field experiments, an assessment also had to be made of the 
ethical aspects22 besides the required health environmental risk assessment. The government at the 
time was unable to reach an agreement on that point. The following government, without the Green 
parties, subsequently decided to drop this part and published the Royal Decree of 21 February 2005. 
A Royal Decree of 3 August 200723 transposes, as the deliberate release into the environment, the 
transport and placing on the market of genetically modified organisms is concerned, the relevant 
provisions of Directive 2004/25/EC on environmental liability with regard to the prevention and 
remedying of environmental damage24. 
 
c) The following Regional legislation on the contained use of GMOs and pathogens have been 
adopted: 
- Flemish Region: Decree of 28 June 1985 on environmental licences (in particular Articles 19c and 
22b); Regulation of the Flemish Government of 6 February 1991 establishing the Flemish Regulations 
governing environmental licences (VLAREM I) (in particular Articles 1, 30°, 57b to 57i and Section 51 
of Annex 1 and Annexes 15, 16 and 17); Regulation of the Flemish Government of 1 June 1995 on 
general and sectorial provisions relating to environmental safety (VLAREM II) (in particular Chapter 
5.51 and Annexes 5.51.3 – 5.51.5); 
- Walloon Region: Decree of 11 March 1999 on environmental licences; Walloon Government 
Regulation of 4 July 2002 establishing the sectorial and integral conditions for the contained use of 
genetically modified or pathogenic organisms; 
- Brussels-Capital Region: Ordinance of 5 June 1997 on environmental licences; Regulation of 8 
November 2001 of the Brussels-Capital Government on the contained use of genetically modified 
and/or pathogenic organisms and on the classification of the installations concerned. 
 
d)  We should also mention the Act of 28 April 2005 amending the Act of 28 March 1984 on 
patents as regards the patentability of biotechnological inventions, which transposes Directive 
98/44/EC of the European Parliament and of the Council of 6 July 1998 on the legal protection of 
biotechnological inventions into Belgian law. 
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2. Regulatory mechanisms in GMO regulation  
 
Various regulatory mechanisms apply, depending on the application: 
 Contained use of GMOs 
 Deliberate release of GMOs into the environment – placing on the market for cultivation  
 GMOs in Food and Feed  
 
 
2.1. Contained use of GMOs 
 
As mentioned before, in the 3 regions the contained use of GMOs is subject to the respective 
(regional) environmental notification and permit systems. In Belgium there are over 400 facilities that 
are approved for contained use with GMOs and/or pathogens. 
 
In the Flemish Region e.g. establishments in which organisms are genetically modified or where such 
organisms are grown, stored, transported, destroyed, discarded or otherwise used need an 
environmental permit or notification. Depending on de risk level of the activities concerned, they 
need prior notification with the municipal government (risk level 1) or a permit of the provincial 
government (risk levels 2 to 4). Apart from that, for each new contained use of GMOs a prior 
notification and in some cases a consent is needed on the basis of a public notification dossier and a 
technical dossier, containing a risk analysis that will be assessed by the Biosafety and Biotechnology 
Unit (SBB) of the Scientific Institute of Public Health (WIV-ISP). The content of the dossiers varies 
according to the safety level of the planned contained use. SBB will deliver an opinion to the 
competent authority, being the Environmental Permitting Division of the Department for the 
Environment, Nature and Energy of the Flemish Region that will decide on the application. The 
contained use can start the day after the consent is delivered or notification has been done, 
depending on the risk level of the contained use. The competent authority will determine, according 
the risk level, the general and specific containment and protection measures on the basis of the 
ALARA-Principle. The approach is based on Directive 2009/41/EC of the European Parliament and of 
the Council of 6 May 2009 on the contained use of genetically modified micro-organisms. A General 
Regulation of the Flemish Government (Chapter 5.51 VLAREM II) determines the general conditions 
under which the activities can take place25. Similar provisions apply in the other regions. 
 
Similar procedures apply in the Walloon Region and the Brussels Capital Region26. 
 
Safety of workers is regulated on the federal level by the Royal Decree of August 4, 1996 concerning 
the protection of works from risks related to exposure to biological agents at work, as amended 
several times. It implements Directive 2000/54/EC of the European Parliament and of the Council of 
18 September 2000 on the protection of workers from risks related to exposure to biological agents 
at work. It is also based on risk assessment and 4 different risk levels. 
 
 
2.2 Deliberate release into the environment and placing on the market of GMOs 
 
2.2.1. Legal framework 
 
The deliberate release of GMOs into the environment and the marketing of GMOs and products that 
contain GMOs, has been regulated on the federal level, based on the articles 132-132d of the Federal 
Act of 20 July 1991, by the Royal Decree of 21 February 2005 regulating the deliberate release into 
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the environment and placing on the market of genetically modified organisms as or in products27. This 
Royal Decree transposes Directive 2001/18/EC of the European Parliament and of the Council of 12 
March 2001 on the deliberate release into the environment of genetically modified organisms, as well 
as Council Decision 2002/812/EC of 3 October 2002 establishing pursuant to Directive 2001/18/EC of 
the European Parliament and of the Council the summary information format relating to the placing 
on the market of genetically modified organisms as or in products and Council Decision 2002/813/EC 
of 3 October 2002 establishing, pursuant to Directive 2001/18/EC of the European Parliament and of 
the Council, the summary notification information format for notifications concerning the deliberate 
release into the environment of genetically modified organisms for purposes other than for placing 
on the market.  
 
2.2.2. Precautionary Principle 
 
As the Directive (Article 1), the Royal Decree of 21 February 2005 (Article 1) provides that the 
objective of the Decree is, “in accordance with the precautionary principle”, to protect human health 
and the environment when carrying out the activities covered by the Directive and the Decree28.  
Both the deliberate release of GMOs and placing on the market of GMOs as or in products are 
subject to the prior written authorization of the competent federal ministers (Articles 3 and 4). In 
order to obtain such authorization, a notification must be submitted along with a health and 
environmental risk assessment of which the requirements in terms of content are specified in Annex 
II. That same Annex also makes reference to the precautionary principle. In his risk assessment, the 
notifier must ensure that an accurate assessment is made on a case-by-case basis of the potential 
adverse effects on human health and the environment, which may occur directly or indirectly. This 
assessment must be conducted according to the nature of the organism introduced, the intended use 
and the receiving environment. Annex III imposes more specific requirements in this connection.  
 
2.2.3. Notification and Assessment 
 
In the standard procedure under the Royal Decree of 21 February 200529, the notification dossier 
must be submitted to the Federal Department of Health, Food Chain Safety and Environment30. This 
authority investigates, together with the Biosafety and Biotechnology Unit (SBB), the admissibility of 
the dossier within 15 days after receipt thereof. If the dossier is found admissible, a European 
identification number is assigned and a copy of the dossier is sent to each of the competent minister 
of the region where the deliberate release will be conducted and to the Biosafety Advisory Council. At 
the same moment also a public consultation starts that lasts for a month.   Both the deliberate 
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release of GMOs and placing on the market of GMOs as or in products are subject prior to the 
written authorization of the competent federal ministers (Articles 3 and 4). In order to obtain such 
authorization, a notification must be submitted along with a health and environmental risk 
assessment of which the requirements in terms of content are specified in Annex II. 
 
In case of a notification for a field trial, the Biosafety Advisory Council delivers an opinion within 65 
days; this opinion is communicated to the competent authority and the relevant regional minister(s). 
Where appropriate, the Biosafety Advisory Council, in delivering its opinion or takes into 
consideration comments of the other Member States, and relevant comments by the public. The 
competent authority subsequently submits a decision to the relevant federal Ministers, who decide 
in agreement with the territorially competent regional Minister31. The competent regional Minister 
has a veto-right and can block the authorization of the release. The Ministers or their representatives 
adopt a reasoned decision within 90 days following the admissibility decision of the notification. This 
decision may consist in authorizing the release, subject to the conditions under which such release 
may take place; the authorization decision lays down at least the conditions put forward by the 
territorially competent regional minister. If the proposed release does not comply with the 






The notification comprises a technical dossier which must contain a monitoring plan in accordance 
with the applicable parts of Annex III in order to identify the effects of the GMO or GMOs on human 
health and the environment. It also comprises the planned self-monitoring measures, information 
concerning the monitoring, the remediation measures, waste processing and the planned emergency 
measures. Annex III to the Royal Decree imposes more specific requirements in this connection. 
Supervision of compliance with the conditions of authorization is entrusted to the Directorate-
General for the Protection of Public Health: Medicines for medical GMOs and to the service of the 
Federal Department of Health, Food Chain Safety and Environment designated by the Minister for the 
other GMOs. The Minister ensures that emergency measures are taken if a serious risk occurs, such 
as suspending or terminating the placing on the market, and notifies the general public through the 
internet site. Before taking such a decision, the Minister offers the authorization holder the 
opportunity to give his comments verbally or in writing, except in duly justified cases of extreme 
urgency. The competent authority notifies the Biosafety Advisory Council, the European Commission 
and the other Member States of the actions that have been taken and states the reasons for the 
decision.  
 
New information/Safeguard clause  
 
Article 42 of the Royal Decree contains the safeguard clause. This clause provides that if the 
competent federal Minister, on the basis of new or additional information which has become 
available after authorization has been granted and which may have an impact on the assessment of 
the health or environmental risks, or on the basis of the reassessment of the existing information in 
the light of new or additional scientific knowledge, has sufficient reason to assume that a GMO as a 
product or in products that has already been the subject of a proper notification dossier and of a 
written consent that was delivered in accordance with the Royal Decree or by virtue of a different 
licensing system of a Member State, poses a risk to human health or to the environment, the 
Minister may provisionally restrict or prohibit the use or sale of that GMO as a product or in products 
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on “its territory” (this probably means the Belgian territory). The competent authority is responsible 
for the EU procedure intended to take a decision regarding a modification or withdrawal of the 
conditions of authorization. For this purpose it shall, where appropriate, request the opinion of the 
Biosafety Advisory Council (Art. 42). 
 
 
2.2.5 Public Participation in case of a field trial 
 
The public is informed on a request for authorisation for deliberate release of a GMO, i.e. field trial, 
mainly through the official Internet sites (Art. 11), which forms part of the general site of the Federal 
Department of Health, Food Chain Safety and Environment. Within 5 days from the date of the letter 
confirming the admissibility of the notification, the competent authority organizes a consultation of 
the public. This consultation period lasts 30 days. During this period, the competent authority 
publishes the following information on the Internet site: the notification, except the confidential 
data; the summary of the notification and the information intended for the general public. In the 
case of clinical trials with human medicines, the publication on the Internet must not infringe privacy 
or medical secrecy. Other than in the case of clinical trials, the competent authority sends a copy of 
the notification, except the confidential data, to the mayor of the municipality or municipalities 
where a deliberate release is planned. Immediately upon receipt of this notification, the mayor 
informs the general public by posting a “notice of consultation” at the town hall. This notice remains 
posted for the whole duration of the public consultation. Throughout the consultation period, the 
notification, except the confidential data, is accessible to the public during the opening hours of the 
town hall and at least once a week until 8 pm or on Saturday morning, in the place which the 
municipal authority has designated in the notice of consultation. The public can transmit its 
comments to the competent authority over the Internet site or by letter. Within 10 days following 
the public consultation, the competent authority informs the relevant federal Minister and the 
regional ministers of the observations made by the public and passes the observations in connection 
with biosafety on to the Biosafety Advisory Council (Art. 17). The Biosafety Advisory Council must 
investigate the comments by the public, and a summary is made of the public consultation as part of 
the decision report that is submitted to the competent Ministers (Art. 18(1)). Since the decision of 
the competent Ministers must be properly reasoned, it will also need to specify to what extent the 
comments of the public have been taken into consideration (Art. 18(3)). No later than one month 
after the decision, the following information is published on the Internet site: the opinions, decisions 
and amendments, and the reports of the competent authority and the supervisory office. The public 
can also consult the full notification, except the confidential data, by simple request to the 
competent authority (Art. 21). Article 43 provides that the Minister, the regional Ministers, the 
Supervisory Office, the Biosafety Advisory Council and the SBB must not divulge to third parties any 
confidential information that was notified or exchanged under the Royal Decree or Directive 
2001/18/EC; they must also protect intellectual property rights relating to the data received. The 
notifier may indicate the information in the notification, the disclosure of which might harm his 
competitive position and which should therefore be treated as confidential. Verifiable justification 
must be given in such cases. It is the competent authority which, after consultation with the notifier, 
decides which information will be kept confidential, and informs the notifier and the competent 
regional ministers of its decision. Article 43(4) provides that in no case the following information may 
be kept confidential: general description of the GMO or GMOs, name and address of the notifier, 
purpose of the release, location of release and intended uses; methods and plans for monitoring of 
the GMO or GMOs and for emergency response; health and environmental risk assessment and the 
opinions of the Biosafety Advisory Council. As was already said, confidential information will not be 
made public, but will form a separate attachment to the notification to which the competent 
authorities naturally do have access. 
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2.2.6. Public participation in case of requests for authorisation of the placing on the market of GMOs  
 
The substance of the regulations dovetails on this point with what has been provided in Articles 12 to 
24 of the Directive 2001/18/EC and the accompanying Annexes. The procedure involves public 
consultation. Article 32 provides that, in order to simplify the public consultation procedure 
organized by the European Commission, the competent authority should publish a summary of the 
notification on the Internet site as soon as the summary of the notification has been forwarded, 
along with information that is intended for the public. From the date of this publication, the public 
has 30 days in which to present observations to the European Commission, and the full notification, 
except the confidential data, can be consulted by simple request to the competent authority. Within 
five days after receipt of the observations made by the public, the competent authority informs the 
Minister of the observations by the public and passes the observations in connection with biosafety 
on to the Biosafety Advisory Council for an opinion. In delivering its opinion, the Biosafety Advisory 
Council must take into account the relevant observations of the public (Art. 31(3)). The Biosafety 
Advisory Council must also take into consideration any observations made by the other Member 
States, in accordance with the procedures for exchange of information. The relevant federal 
Ministers ultimately decide whether, and under which conditions, the Belgian Government 
agrees/disagrees in the EU voting procedure that the GMO in question may be placed on the market.  
  
 
2.2.7. Judicial review 
 
The decision on the notification, the withdrawal of an authorization and a provisional restriction or a 
provisional ban in the context of the safeguard clause are administrative legal acts that can be 
challenged by an action for annulment and an action for suspension before the Council of State. The 
Council of State carries out a legality review. This review not only involves testing such individual 
decisions against higher legal standards (European law, Constitution, Statutes and Royal Decrees), 
but also against the formal obligation of justification and the principles of good government. Both 
substantive and formal aspects are concerned. Both natural and legal persons who can prove an 
interest can bring such an action within 60 days after they have been notified of the challenged 
decision. For the Council of State, the interest in question must be a personal, direct, positive and 
legitimate interest. There must always be an individualized connection between the applicant and 
the challenged legal act. The act in question must be prejudicial, in other words, it must cause a 
certain disadvantage to the person bringing the action. However, it can concern a minor material or 
even purely moral interest32. There is little doubt that the neighbouring residents or farmers of a test 
field have a sufficient interest. Public (e.g. municipal authority) or private legal entities (e.g. non-
profit conservation organizations) can take action before the Council of State. In the latter case, it is 
examined whether the organization has the necessary authority to defend the collective interest 
which it has defined in its bylaws, in other words, whether it is sufficiently representative33. When 
the Council of State annuls a decision, the administrative procedure must be resumed and the 
administrative authority is bound by the judgment of the Council of State. Consequently, it will have 
to make sure that it does not commit the same breach again. In the case of a manifest infringement 
or a serious risk of infringement of this legislation, an action for suspension may be brought before 
the President of the Court of First Instance. This can also be done by non-profit organizations which 
have been incorporated for at least three years and which can prove that there is an actual activity 
going on that corresponds to their corporate purpose and that this activity is connected with a 
collective environmental interest which they seek to protect. Individual citizens can indirectly also 
bring such an action, more particularly “on behalf of the municipality”, in the event that the 
municipal authority refuses to institute such an action34. 
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2.2.8 Practical experiences 
 
An overview of concluded and ongoing procedures of notifications of activities with GMOs can be 
found on the website of the Belgian Biosafety Advisory Council35. 
 
For concluded procedures, the website provides details and further links to, inter alia: 
 
 Notifications for deliberate release of GMO's (GM plants and other) for any other purpose 
than for placing on the market  
 Notifications for transgenic plants to be placed on the EU market under Directive 2001/18/EC 
- Part C 
 Notifications submitted under Regulation (EC) N° 1829/2003 on genetically modified food 
and feed 
 Notifications submitted under the Novel Food Regulation (EC) N° 258/97 
 
There have been quite a number of notifications for deliberate release of GMOs in Belgium for 
purposes other than placing on the market. These concerned mainly field trials with GM plants and 
clinical trials with GMOs other than plants.  
 
So far, only one authorization has been granted through Belgium for the placing on the market of 
GMOs, more particularly for the “commercial release of MS8, RF3 and MS8xRF3 oilseed rape”, to 
Bayer Crop Science. The authorization has been given for import and processing for nutritional 
purposes; no authorization has been given for cultivation. The decision was delivered by the 
European Commission, because no qualified majority was reached at the Regulatory Committee and 
at the Council level.  
 
 
2.2.9. Coexistence and GMO-free zones 
 
In both the Flemish and Walloon Region a general legal framework on coexistence of genetic 
modified cultures with conventional and organic cultures has been adopted in view of the 
implementation of article 26a of Directive 2001/18/EC (as amended by Directive 2008/27/EC).  
 
The Decree of 3 April 2009 of the Flemish Region36, which is applicable to all cultures of GMOs in that 
region that would be authorised in the framework of Directive 2001/18/EC, aims to ensure the free 
choice of farmers between GMO, conventional and organic cultures and to avoid economic losses for 
conventional and organic cultures due to unintended presence of GMOs above the EU threshold 
value for labelling. It obliges farmers (and their contractors) who intend to cultivate GMOs to follow a 
specific training. They have to notify in advance the Flemish authorities and neighbouring farmers of 
that intention. These neighbouring farmers can object to the intended culture on the basis of a 
reasoned proper economic interest. The farmers who cultivate GMOs have to contribute to a Public 
Fund for compensation of economic losses. A Coexistence Commission, composed of representatives 
of various administrations and scientific experts, has to assess the objections from neighbouring 
farmers and the applications for compensation. All cultures of GMOs are registered in a public 
register. On the basis of this Decree, the Flemish Government has adopted some general rules 
concerning coexistence37, as well as rules specific for maize, potatoes and sugar beet38.  
                                                          
35
 http://www.bio-council.be/bac_proc_in.html  
36
 Belgian Official Journal,  4 May 2009. 
37
 B.Vl.Reg. van 15 oktober 2010 houdende de vaststelling van algemene maatregelen voor de co-existentie van 




In the Walloon Region, the Decree of 19 June 2008 addresses co-existence. The Executive Order of 
the Walloon Government, implementing the Decree39, provides for the possibility to establish GMO-
free zones.  Such a zone consists of arable land of at least 3 farmers and covering at least 150 
hectares. The concerned farmers may introduce a demand for the instauration of such a zone, and 
when approved, with limitations on GMO cultivation for adjacent land as a consequence40. Apart 
from that it has been suggested that 124 municipalities and the Walloon Region have declared 
themselves GMO-free . Such declarations have no legal consequences.  
 
A comparison between the various systems shows that the specific rules for crops are much more 
stringent in the Walloon region than in Flanders. For instance the isolation distance for GM maize is 
in Flanders 50 meters, where in Wallonia it is 600 meters, de facto making GM maize cultivation very 
virtually impossible. There is also a big difference in the intent with which the Flemish and Walloon 
coexistence legislation was written. See „general information“. 
 
In January 2014, the region of Brussels proposed draft legislation that the around 260 hectares of 




2.3. GMO in food production 
 
2.3.1 Regulation (EC) No 1829/2003 
 
This matter is regulated on the EU level by Regulation (EC) No 1829/2003 of the European Parliament 
and of the Council of 22 September 2003 on genetically modified food and feed. This Regulation 
provides the basis for ensuring a high level of protection of human life and health, animal health and 
welfare, environment and consumer interests in relation to genetically modified food and feed, 
whilst ensuring the effective functioning of the internal market. It lays down EU procedures for the 
authorisation and supervision of genetically modified food and feed provisions for the labelling of 
genetically modified food and feed (Art. 1). Chapter II deals with the authorisation, supervision and 
labelling of genetically modified food, while chapter III does the same for genetically modified feed. 
Chapter IV contains common provisions for both applications.   
 
2.3.2. Co-operation between national and EU bodies 
 
The industrial operator can submit his application in accordance with this Regulation for all food 
products containing GMOs in compliance with the provisions provided for by Directive 2001/18/EC 
on the deliberate release of GMOs into the environment. The industrial operator can submit a single 
application for food and feed uses and for cultivation. This means that a GMO that has obtained 
authorisation can be used not only in food and animal feed but also for cultivation or deliberate 
release into the environment. Once the application has been made by an industrial operator, the 
receiving national authority concerned acknowledges receipt in writing within 14 days and informs 
                                                                                                                                                                                     
38
 B.Vl.Reg. van  15 oktober  2010 houdende de vaststelling van specifieke maatregelen voor de co-existentie 
van genetisch gemodificeerde maïsgewassen met conventionele maïsgewassen en biologische maïsgewassen, 
BS 30 November 2010; B.Vl.Reg. van 10 november 2011 houdende de vaststelling van specifieke maatregelen 
voor de co-existentie van genetisch gemodificeerde aardappelgewassen met conventionele 
aardappelgewassen en biologische aardappelgewassen, BS 23 December 2011; B.Vl.Reg. van 10 november 
2011 houdende de vaststelling van specifieke maatregelen voor de co-existentie van genetisch gemodificeerde 
suikerbieten met conventionele suikerbieten en biologische suikerbieten, BS 23 December 2011. 
39
 A.G.w. du 7 mars 2009 relatif à la coexistence des cultures génétiquement modifiées avec les cultures 
conventionnelles et les cultures biologiques, BS 27 March 2009. 
40
 Art. 30 and 31.  
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the European Food Safety Authority (EFSA), which is responsible for risk assessment in the food 
sector. The latter has 6 months in which to conduct this assessment. The Commission is responsible 
for risk management. On the basis of the risk assessment carried out by the EFSA, the Commission 
draws up within 3 months a draft decision accepting or rejecting the application. It then submits this 
draft to the Standing Committee on the Food Chain and Animal Health. If this committee accepts the 
proposal, it is finally adopted by the Commission; if it does not, the proposal is assessed by an appeal 
committee (NB: In the new comitology procedure, the Council of Ministers is replaced by an appeal 
committee. The difference between the Standing committee and the appeal committee is that the 
first is populated with member state ‚experts‘, where the second is populated with member state 
‚diplomats‘.). If the latter does not reach a position within three months or if it is unable to reach a 
qualified majority for or against, the Commission may adopt its proposal. The marketing 
authorisation is given for a period of maximum 10 years and is renewable. 
 
 
2.3.3  Enforcement  
 
The Regulation is in Belgium enforced by the same authorities as those that intervene in the national 
procedures. The websites show the applications for authorization and the public consultations and 
inquiries under way by a link to the European website. The opinions of the Biosafety Advisory Council 
are published on its own website. So far, more than fifty opinions have been delivered with regard to 
EU applications41. Decisions of the European Commission fall outside the jurisdiction of the Belgian 
courts. Such decisions can only be challenged before the EU Courts (General Court or Court of 
Justice) under the conditions set out in Article 263(4) of the TFEU. As is known, the Court of Justice 
upholds in this matter a very strict interpretation of the criterion “of direct and individual concern”.  
It has to be seen if under the new additional criterion “a regulatory act which is of direct concern to 
them and does not entail implementing measures“ Commission decisions such as resulting from the 
Regulation, can be challenged by interested parties.  The matter can also arise before a national 
court of law. That Court must then of course refer the case to the European Court of Justice for a 
preliminary ruling on the validity of the decision of the European Commission (art. 267 TFEU). 
 
 
2.3.4. Role of Belgian Biosafety Advisory Council 
 
The Regulation provides that the EFSA may ask the appropriate food assessment body of a Member 
State or a competent authority designated in accordance with Article 4 of Directive 2001/18/EC to 
carry out assessments (Art. 6(3)(b) and (c)). In case the application covers cultivation, EFSA must  
consult a MS. Belgium has received a mandate from EFSA for the evaluation of 4 cultivation 
applications. 
 
The national competent authority receives the applications for authorization and the EFSA informs 
the European Commission and the other Member States of the applications (Art. 5(2)(a) and (b)). 
Although the Regulation does not say so in so many words, the purpose of those applications could 
not be other than to allow the competent authorities to express their views on the matter during the 
course of the procedure, either in the form of an opinion to the EFSA, or through the public 
consultation procedure, or by taking part in the Committee referred to in Article 35. In practice, the 
Belgian Biosafety Advisory Council delivers an opinion. It is current practice that all member states‘ 
biosafety advisory bodies participate in commenting to a dossier, before the EFSA opinion is formed. 
EFSA consults the member states. This means that in Europe more than 200 people are actively 
involved in assessing a dossier. In Belgium the Biosafety Advisory Council provides a formal advice 
after the EFSA GMO panel has formulated its opinion. 







2.3.5 Thresholds  
 
A threshold value is referred to in Regulation (EC) No 1830/2003 of the European Parliament and of 
the Council of 22 September 2003 concerning the traceability and labelling of genetically modified 
organisms and the traceability of food and feed products produced from genetically modified 
organisms. This Regulation covers all products which consist of GMOs or which contain (processed) 
products from  GMOs(this includes fields as diverse as the products, which are intended for entry 
into the human or animal food chain, products destined for industrial processing for uses other than 
consumption (e.g. in the production of biofuel) or even products destined to be used ornamentally 
(e.g. in the production of cut flowers)) and foodstuffs and animal feed products made from GMOs. All 
the products covered by this Regulation are subject to compulsory labelling, which shall enable 
consumers to be better informed and will offer them the freedom to choose to buy products 
consisting of, containing or made from GMOs. Traceability enables GMOs and their products to be 
traced throughout the production chain. This system is based on the transmission and holding of 
information by each operator. All food or feed products, including those intended directly for 
processing are subject to the labelling obligation when they consist, contain or are made from GMOs. 
Only traces of approved GMOs are exempt from this obligation if the ingredients do not exceed the 
threshold of 0.9 % and if their presence is adventitious and technically unavoidable. The Member 
States carry out measures for the inspection and monitoring of products, including sampling and 
quantitative and qualitative analyses of food and feed. These measures entail the Member States 
being able to withdraw from the market a product that does not meet the conditions laid down in 
this Regulation. So far, no additional laws or regulations have been adopted at the national level with 
a view to the implementation of Regulation 1830/2003. Inspection is carried out by the Federal 
Agency for the Safety of the Food Chain.  
 
 
2.3.6. Implementation and enforcement, controlling regime 
  
Supervision of compliance with the conditions of authorizations is entrusted to the Directorate-
General for the Protection of Public Health: Medicines for medical GMOs and to the service of the 
Federal Department of Health, Food Chain Safety and Environment designated by the Minister for the 
other GMOs. They have broad supervising powers, including the power to take safety measures (Art. 
132a of the Act of 20 July 1991, as amended by the Act of 1 March 2007). The penalty provided for 
essentially consists of the right of the Minister to withdraw the consent. Such withdrawal can be 
resorted to if the conditions for obtaining the authorization are not or no longer satisfied, and no 
alternative settlement is arrived at between the holder of the authorization and the Minister or his 
representative, where appropriate after the opinion of the Biosafety Advisory Council has been 
sought. Authorization can also be withdrawn if incorrect or misleading information has been given, 
on the basis of which the authorization had been granted. Before withdrawing an authorization, the 
Minister offers the authorization holder the opportunity to give his comments verbally or in writing, 
except in duly justified cases of extreme urgency (Art. 24 of the Royal Decree of 25 February 2005). 
Violations can be penalized by the criminal court with 1 month’s to 8 years’ imprisonment and a fine 
of 6,000 euros to 60,000,000 euros or, in case of non-prosecution, by the administrative authority 
with an administrative fine of at least 6,000 euros and up to 30,000 euros (Art. 132c and 132d of the 
Act of 20 July 1991, as amended by the Act of 1 March 2007). Inspection of Regulations 1829/2003 
and 1830/2003 is carried out by the Federal Agency for the Safety of the Food Chain42.  
 
  




3. Labelling  
 
3.1. Labelling regime  
 
Apart from the provisions laid down in Regulation (EC) No 1830/2003 of the European Parliament 
and of the Council of 22 September 2003 concerning the traceability and labelling of genetically 
modified organisms and the traceability of food and feed products produced from genetically 
modified organisms. According to Art. 11 of that Regulation Member States shall lay down the rules 
on penalties applicable to infringements of this Regulation and shall take all measures necessary to 
ensure that they are implemented. The penalties provided for must be effective, proportionate and 
dissuasive. Member States shall notify those provisions to the Commission, not later than 18 April 
2004 and shall notify it without delay of any subsequent amendment affecting them. No specific 
national rules in this respect have been adopted. However general labelling requirements are laid 
down in different Articles of the Royal Decree of 21 February 2005, and those provisions are subject 
to the sanction provisions of the Act of 20 July 1991 and the various sectorial Acts governing specific 
categories of goods, products or materials (Art. 49 of the Royal Decree). 
 
 
3.2. Legislation addressing labelling fraud 
 
When the labelling requirements provided for by the Royal Decree of 21 February 2005 are not 
observed, the sanctions of the Act of 20 July 1991, provided for in Art. 132b, apply.  The competent 
inspectors can also seize or confiscate GMOs and products containing GMOs that are not in 
conformity with the regulations (Art. 132a). Similar powers are given under the Act of 24 January 
1977 protecting the health of consumers with regard to food stuff and other products and under the 
Act of 21 December 1998 concerning product standards promoting sustainable production and 
consumption patterns and protecting the environment, public health and the workers. Articles 10 
and 11 of the Act of 6 April 2010 concerning market practices and consumer protection contain 
general provisions on labelling. It contains also a section on unfair commercial practices inspired by 
Directive 2005/29/EC concerning unfair business-to-consumer commercial practices in the internal 
market43. A practice is misleading if it contains false or untrue information or is likely to deceive the 
consumer. Unfair commercial practices can be combatted trough an action for cessation. The articles 
110-118 of the Act of 6 April 2010 organise a private enforcement remedy through injunctive relief. 
The range of parties entitled to institute proceedings for infringement of any provisions of the act is 
very broad: the parties concerned the Minister of Economic Affairs, the Director-General of DG 
Enforcement and Mediation, trade organisations and consumer organisations. The President of the 
Commercial Court may order the cessation or the prohibition of any breach of the Act. In addition, 
the President can order that the judgement or a corrective statement should be published. Art. 123 
of The Act establish an administrative warning procedure. Warnings may be issued by the Minister or 
the officials designated by the Minister, requesting that the undertaking concerned cease the 
infringement. The infringer may undertake to cease the infringement, and, where appropriate, that 
undertaking may be published. If the infringer dies not obey, the Minister of Director-General may 
initiate legal action for a cease and desist order, a settlement can be made or criminal enforcement 
can be started44 
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 B. KEIRSBILCK, The New European Law of Unfair Commercial Practices and Competition Law, Oxford and 
Portland, Hart Publishing, 2011,  702 p. 
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4.1. Genetic technology 
 
As civil liability for damage against persons, goods or economic interests is concerned, there is no 
specific legislation on liability for GMO-related activities. The general fault based liability of Art. 1382 
of the Civil Code is applicable. A breach of a statutory duty (including duties imposed by GMOs 
legislation) or the general duty of care qualifies as a fault. Compensation for personal injury, direct 
property damage and the ensuing economic losses, is possible, provided that a causal link can be 
proven between these damages and the fault45. Pure ecological damage is not covered.  However, 
the Royal Decree of 21 February 2005 provides that the notification of a deliberate release for other 
purposes than placing on the market must contain a signed declaration of civil liability (Art. 13(1)(f)). 
This declaration reads: “I, the undersigned notifier,…, hereby assume full civil liability for any damage 
caused to human and animal health, property or the environment as a result of the tests”. The scope 
of this clause is limited. It does not alter the common fault liability for damage that is based on 
Article 1382 of the Civil Code46. At most, it may cause the liability for damage to be channelled to the 
notifier. 
 
As indicated above, in the Walloon and Flemish regional legislation on co-existence there is an 
obligation of farmers who cultivate GMOs to compensate the economic losses that may be caused to 
conventional or organic cultures, including the obligation to buy the harvest that cannot be placed on 
the market because of (involuntary) admixture. The GMO farmers have to pay a contribution to a 
Fund that will compensate for the economic losses . 
 
As liability under public law is concerned, the federal and regional legislation, adopted in view of the 
implementation of Directive 2004/35/CE of the European Parliament and of the Council of 21 April 
2004 on environmental liability with regard to the prevention and remedying of environmental 
damage, is relevant47. De federal legislation – the Royal Decree of 3 August 200748 – is applicable for 
environmental damage that is caused by the deliberate release into the environment, the transport 
and placing on the market of GMOs. The regional legislation49 is applicable when environmental 
damage is caused by any contained use, including transport, involving genetically modified micro-
organisms. The purpose of the Environmental Liability Directive (“ELD”), and the Belgian legislation 
that transpose it,  is to establish a so called ‘administrative’ framework of environmental liability, 
based on the "polluter-pays" principle, to prevent and remedy environmental damage, via a public 
law approach. The ELD aims at ensuring that the financial consequences of certain types of harm 
                                                          
45
 B.A. KOCH, “General Report” in B.A. KOCH (ed.), Liability and Compensation Schemes for Damage Resulting 
from the Presence of Genetically Modified Organisms in Non-GM Crops. Reports, April 2007, 45-53, 
http://ec.europa.eu/agriculture/analysis/external/liability_gmo/full_text_en.pdf; V. WILCOX, “Summaries of 
the Country Reports” in B.A. KOCH, op. cit., p. 129 ; B. DUBBUISSON & G. GATHEM, “Belgium” in B.A. KOCH 
(ed.), Liability and Compensation Schemes for Damage Resulting from the Presence of Genetically Modified 
Organisms in Non-GM Crops. Annex I. Country Reports, April 2007, p. 32 – 50,  
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 B. DUBBUISSON & G. GATHEM, loc. cit., p. 33. 
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 B. DUBBUISSON & G. GATHEM, loc. cit., p. 33; W. XIANG, op. cit., p. 175-182. 
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 Royal Decree of 3 August 2007 concerning prevention and remedying of environmental damage due to the 
placing on the market of GMOs and products containing GMOs, Belgian Official Journal,  20 September 2007. 
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prevention and remedying of environmental damage, Belgian Official Journal, 14 November 2008; Flemish 
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Belgian Official Journal, 12 February 2008; Walloon Region:  Decree of 22 November 2007, amending Book I of 
the Environmental Code with regard to the prevention and remediation of environmental damage, Belgian 
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caused to the environment will be borne by the economic operator who caused this harm. The 
competent authorities shall ensure the effective implementation and enforcement of the ELD. They 
are for instance, in charge of specific tasks such as assessing the significance of the damage and 
determining which remedial measures should be taken (in co-operation with the liable operator). An 
operator is any natural or legal, private or public person who operates or controls the damaging 
occupational activity, including the holder of a permit or authorisation for such an activity or the 
person registering or notifying such an activity. However, due to the definition and the thresholds 
provided for in the definition of environmental damage, it is not likely that GMOs related activities 
will cause damage in the sense of the ELD. 
 
 
4.2. Product liability 
 
The Act of 25 February 1991 on the liability for products with defects50 implements directive 
85/374/EEC of 25July 1985 on the approximation of the laws, regulations and administrative 
provisions of the Member States concerning liability for defective products. GMOs, including 'primary 
agricultural products'51, and products containing them, can fall under the scope of this piece of 
legislation if damage is caused by product that is defective. A product is understood to be defective 
“when it does not provide the safety which a person is entitled to expect, taking all circumstances into 
account, including: (a) the presentation of the product;  (b) the use to which it could reasonably be 
expected that the product would be put; (c) the time when the product was put into circulation”52. 
The strict liability system - channelled to the producer  and provided that none of the defences is 
applicable -  covers only (a) damage caused by death or by personal injuries; (b) damage to, or 
destruction of, any item of property other than the defective product itself, with a lower threshold of 
500 EUR, provided that the item of property: (i) is of a type ordinarily intended for private use or 




                                                          
50
 Belgian Official Journal, 22 March 1991. 
51
 B. DUBBUISSON & G. GATHEM, loc. cit., p. 40. The Belgian Act has not implemented the exception of  
“primary agricultural products and game” being “ the products of the soil, of stock-farming and of fisheries, 
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52
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circulation; B. DUBBUISSON & G. GATHEM, loc. cit., p. 35. 
53
 B.A. KOCH, loc. cit., 55-56; V. WILCOX, loc. cit., p. 130; B. DUBBUISSON & G. GATHEM, loc. cit., p. 39 - 40. 
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5. Discussion  
 
Returning to the overall topic of this report and the underlying conference, “Policies and regulations 
with regard to genetic technology and food security”, the authors offer the following general 
observations. 
 
As for all EU countries, regulation of genetic modification and of GMOs in Belgium is to a large extent 
shaped by the EU regulatory framework for GMOs. 
 
The regulatory situation for GMOs in the EU knows some complexities:   
 
 The EU regulatory framework entails Directives, Regulations, Decisions and Guidelines, each 
with their own objective, scope and legal basis (for example, Directive 2009/41/EC is an 
‘environmental protection’ directive, whereas Directive 2001/18/EC is an ‘internal market’ 
directive);  
 Some decisions within this framework are collective decisions, in which the Member States, 
EFSA and the European Commission play a role. 
 The implementation on the national level, involves in many Member States various 
governmental levels, ranging from the national or federal level, via regional or provincial 
levels, to local levels. Belgium is a good example of this, whereby there is a division in 
competencies between the federal government and the regions54. 
 
As of the second half of the 90s, the part of the regulatory system addressing placing the market of 
GMO products, started to stagnate, and consequently the EU Member States and Institutions have 
revised the regulatory framework in various steps, such as: 
 
 Directive 2001/18/EC – amendments of the original Directive on Release into the 
Environment  
 Adoption of the Regulation (EC) N° 1829/2003 (genetically modified food and feed), and 
1830/2003 (traceability and labelling) 
 Adoption of Commission Implementing Regulation (EU) n° 503/2013 on applications for 
authorisation of genetically modified food and feed. 
 
Despite these and other revisions, there is still much ongoing debate between the Member States 
and the EU institutions to further revise the regulatory framework, and the debate itself indicates 
that very few – if any – of the of the involved parties is content with the current system. 
 
An often heard comment is that the EU regulatory system for GMOs is ‘dysfunctional’, whereby 
reference is made to the discrepancy between the significant R&D investments by the EU Member 
States and Institutions and the fact that there are so few realisations of that research, in particular in 
the field of agricultural biotechnology.  Another discrepancy that is often referred to is that while 
many millions of tons of GM crops cultivated outside the EU are approved and imported  for food 
and feed use in the EU, while European farmers are not allowed to grow those same GM crops.  
 
Given the context of this report, i.e. the 19th International Congress of Comparative Law, the authors 
believe that it is appropriate to assess whether the regulatory framework itself can a priori not 
function properly, or that the regulatory framework is not implemented properly.  
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 Supra § 1.3. 
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Following up on the above statement that the EU regulatory framework knows some complexities, a 
first question is whether the system is, also when compared to other systems, too complex.  
 
When compared to regulatory frameworks for GMOs in other parts of the world, we note that 
complexity is not unique for the EU. Regulatory frameworks in other parts of the world know similar 
complexities. For example, the regulatory framework of the United States entails regulations from 
various Government agencies, such as the EPA, the USDA and the FDA, with each their own 
objective, scope and definitions.  
 
When we compare the EU regulatory framework for GMOs with EU regulatory frameworks for other 
topics, then we note that overall there are similar complexities in terms of mixed regulatory tools, 
mixed competencies etc.  
 
The EU regulatory framework for GMOs contains an authorisation system for field trials and placing 
on the market of GMOs and GMO products. As with other authorisation systems, the system for 
GMOs contains standard elements, such as information requirements for requests/applications, rules 
for public involvement and confidentiality of data, time periods, procedures and criteria for decision 
making and the establishment of an independent and highly capable scientific body, i.e. the 
European Food Safety Authority (EFSA).   
 
However, in comparing the EU authorisation system for GMOs that are medicines with the 
authorisation system for GMOs that are not medicines, we do note an important  difference. In the 
decision making process for medicines (GMOs and otherwise) the positive advice of the European 
Medicines Agency (EMA) means approval of a medicine, whereas a positive advice of EFSA has to be 
voted on by a standing committee and later on by an appeal committee of member state 
representatives. 
 
In summary: while leaving aside the question whether the current regulatory framework for GMOs is 
the best way to regulate this technology, the current system overall contains the standard elements 
of an authorisation system, i.e. the system can in principle function as it was designed55. In fact, the 
experiences from the early years of the regulatory system show that the system could and indeed did 
function as it was designed, i.e. allowing authorities to make informed decisions that involve key 
areas such as food security, human health and environment. 
 
A next question is therefore how the authorisation system is applied in practice, e.g. whether 
decisions are taken in accordance with the legal time limits, procedures and criteria.  
 
As various surveys suggest56, for contained use and field trial applications, decisions are generally 
taken in accordance with the legal time limits, procedures and criteria.  
 
Yet, with applications for placing on the market of GMOs and GMO products, the situation is quite 
different, e.g: 
 
 For many applications for placing on the market, the legal time frames for decisions have 
been exceeded with many months and often with years57. 
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 When talking about ‘functioning authorisation systems’ the authors refer to systems whereby decisions are 
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 For many applications the EU Commission has not submitted after the EFSA opinion within 
the legal time frame a draft decision for a vote by Member States. In a ruling of 26 
September 201358, the General Court confirmed that in doing so, the Commission had failed 
in its duties. 
 Several Member States have invoked the ‘safeguard clause’, which allows the provisional 
prohibiting a GMO if there is new scientific information that suggests risk. Despite that EFSA 
has concluded that there was no valid scientific justification for these bans, these bans 
maintained.  
 
As the above examples show, EU Member States  and EU Institutions do not always comply with the 
regulatory system for GMOs that they themselves designed. This is disconcerting in itself, as it affects 
the ‘Rule of Law’, which touches on the question how citizens of the EU can be expected to always 
follow the rules, when Governments and EU institutions do not?  
 
When we look for reasons behind the current situation, then we come to the second topic of this 
section, i.e. “policies”.   
 
Obviously, one of the main reasons for the current situation is that the policies of some governments 
and politicians are no longer the same as they were in the time when the regulatory framework was 
designed, when the focus was on the environment, human health, research and the internal market.   
For some governments and politicians, other aspects have come into the equation, such as current 
societal debates and preferences for certain forms of agriculture, whereby “policies” and “politics” 
sometimes seem intermingled. In that context, the above described difference between 
authorisation systems that do and authorisation systems that do not involve the possibility for 
politics to enter the authorisation process through standing committees and appeal committees, can 
become a fundamental difference with far reaching consequences.  
 
In this perspective it is worth noting that the European Commission has presented a proposal that 
would allow that, after a GM crop is approved on grounds of safety, Member States can ban  
cultivation that GM crop in their territory, for reasons other than safety.  
 
This proposal has received a great variety of reactions, ranging from some Governments and 
organisations welcoming the proposal, to criticism that the proposal would go against the Internal 
Market and the WTO, and that it would affect the predictability of the system that various 
stakeholders (e.g. farmers and research organisations) need to make investments in this area.  
 
The legal implications of this nationalisation proposal would be an excellent topic for further 
discussion in the 19th International Congress of Comparative Law. 
 
Ghent, January 2014  
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